FACIT-fatigue score and treatment quality assessment for paroxysmal nocturnal hemoglobinuria patients treated with Eculizumab in Türkiye.
Measuring patient-reported fatigue alongside standard blood tests reveals that symptom relief and clinical response don't always match in rare blood disorder treatment.
This 6-center multicenter study evaluates FACIT-fatigue and treatment quality metrics in paroxysmal nocturnal hemoglobinuria patients receiving complement inhibitor therapy, identifying discordance between hematological response and patient-reported fatigue outcomes. The findings support comprehensive patient-reported outcome measures as essential co-primary endpoints in future PNH trials and clinical monitoring.
What the study was
- Study design
- Multicenter observational study (PNH, 6 centers)
- Population
- Paroxysmal nocturnal hemoglobinuria (PNH) patients on complement inhibitors
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- PloS one
Why it surfaced
Multicenter evidence gap for patient-reported outcomes in PNH, an ultra-rare blood disease where fatigue is the dominant symptom; directly informs clinical monitoring and trial design for complement therapies.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.